Extended AML Panel BCR/ABL AML/ETO CBFB PML/RARA FLT3 NPM1 CEBPA
Comprehensive Genetic Testing for Acute Myeloid Leukemia
The Extended AML Panel represents a cutting-edge diagnostic approach to Acute Myeloid Leukemia (AML) management, providing clinicians with essential genetic information to guide treatment decisions and predict patient outcomes. This comprehensive panel examines seven critical genetic markers that play pivotal roles in AML pathogenesis, prognosis, and therapeutic response.
What This Advanced Test Measures
Our Extended AML Panel utilizes sophisticated Sanger Sequencing technology to detect specific genetic abnormalities:
- BCR/ABL Fusion Gene: The Philadelphia chromosome translocation, typically associated with CML but occasionally found in AML
- AML/ETO (RUNX1/RUNX1T1): t(8;21) translocation defining a specific AML subtype with favorable prognosis
- CBFB Rearrangements: Inversion 16 or t(16;16) abnormalities associated with core-binding factor AML
- PML/RARA Fusion: t(15;17) translocation characteristic of acute promyelocytic leukemia (APL)
- FLT3 Mutations: Internal tandem duplications (ITD) and tyrosine kinase domain mutations indicating poor prognosis
- NPM1 Mutations: Nucleophosmin gene mutations often associated with favorable outcomes in absence of FLT3-ITD
- CEBPA Mutations: CCAAT/enhancer-binding protein alpha mutations indicating favorable prognosis in specific AML subtypes
Who Should Consider This Genetic Testing?
This comprehensive panel is recommended for individuals presenting with:
- Newly diagnosed Acute Myeloid Leukemia cases
- Unexplained cytopenias with suspicious bone marrow findings
- Patients with myelodysplastic syndromes progressing to AML
- Individuals with family history of hematological malignancies
- Patients requiring risk stratification for treatment planning
- Cases where targeted therapy options are being considered
Clinical Symptoms and Indications
Patients experiencing symptoms such as persistent fatigue, unexplained bruising or bleeding, recurrent infections, bone pain, or abnormal blood counts should discuss genetic testing with their hematologist. Early detection of specific genetic abnormalities can significantly impact treatment success and long-term outcomes.
Key Benefits of Extended AML Panel Testing
- Precise Diagnosis: Identifies specific AML subtypes for accurate classification
- Risk Stratification: Helps determine prognosis and appropriate treatment intensity
- Targeted Therapy Guidance: Identifies patients who may benefit from specific targeted treatments
- Treatment Monitoring: Provides baseline for monitoring minimal residual disease
- Personalized Medicine: Enables tailored treatment approaches based on genetic profile
- Family Risk Assessment: Helps identify potential hereditary factors in some cases
Understanding Your Test Results
Your genetic test results will provide detailed information about the presence or absence of specific mutations. Positive findings for certain translocations like PML/RARA may indicate eligibility for all-trans retinoic acid (ATRA) therapy, while FLT3 mutations might suggest benefit from FLT3 inhibitors. Normal results help exclude specific genetic abnormalities and guide alternative diagnostic considerations. All results should be interpreted by a qualified hematologist or oncologist in the context of your complete clinical picture.
Test Specifications and Pricing
| Test Component | Details |
|---|---|
| Test Name | Extended AML Panel BCR/ABL AML/ETO CBFB PML/RARA FLT3 NPM1 CEBPA |
| Regular Price | $900 USD |
| Discount Price | $676 USD |
| Turnaround Time | 7-8 days |
| Sample Type | Bone marrow / Peripheral blood (Transport immediately) |
| Test Components | EDTA Vacutainer (2ml) |
| Testing Method | Sanger Sequencing |
Nationwide Testing Availability
We have diagnostic centers conveniently located across major US cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.
Book Your Comprehensive Genetic Assessment
Take the first step toward precise leukemia diagnosis and personalized treatment planning. Our experienced genetic counselors and hematology specialists are ready to assist you with comprehensive testing and result interpretation.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your Extended AML Panel testing. Our team will guide you through the testing process, answer your questions, and ensure you receive the comprehensive genetic insights needed for optimal leukemia management.
Note: This test requires a doctor’s prescription for most clinical cases. Prescription requirements do not apply for surgery preparation, pregnancy-related testing, or international travel documentation purposes.
